Overview

* Joint Q2 2025 revenue rises to $13.3 million, up 5% compared to Q2 2024.

* Adjusted EBITDA rises 52% to $3.2 mln, reflecting operational improvements

* Co refranchised 37 clinics, acquired Northwest regional developer territory

Outlook

* Company revises 2025 system-wide sales forecast to $530 mln-$550 mln

* New franchised clinic openings expected to be 30-35 in 2025

Result Drivers

* REFRANCHISING STRATEGY - Refranchised 37 clinics, increasing franchised clinics to 92% of portfolio

* REGIONAL EXPANSION - Acquired Northwest regional developer territory for $2.8 mln

* MARKETING SHIFT - Pivoting marketing strategy towards pain relief to enhance brand campaign

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $13.30

Revenue mln

Q2 $3.20

Adjusted mln

EBITDA

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)